This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA expands indications for Avastin, Keytruda, six gene mutations linked to pancreatic cancer
Click Here to Manage Email Alerts
Among the top stories in hematology/oncology is a study that identified mutations in six genes associated with pancreatic cancer. Higher levels of circulating vitamin D appeared associated with a lower risk for colorectal cancer among women. Other top stories include FDA approval of Avastin plus chemotherapy for ovarian cancer after surgery, dacomitinib improved OS among patients with newly diagnosed, advanced EGFR-positive non-small cell lung cancer, and FDA approval of Keytruda for adults and pediatric patients with primary mediastinal large B-cell lymphoma.
Six gene mutations linked to pancreatic cancer
Researchers identified mutations in six genes associated with pancreatic cancer, according to study results published in JAMA. Read More.
Higher vitamin D levels associated with lower colorectal cancer risk for women
Higher circulating vitamin D levels appeared associated with a lower risk for colorectal cancer among women, according to findings published in Journal of the National Cancer Institute. Read More.
FDA approves Avastin plus chemotherapy for ovarian cancer after surgery
The FDA approved bevacizumab for use with chemotherapy, followed by bevacizumab as a single agent, for the treatment of women with advanced ovarian cancer who underwent initial surgical resection. Read More.
Dacomitinib new first-line treatment option for EGFR -positive non-small cell lung cancer
Dacomitinib improved OS compared with gefitinib among patients with newly diagnosed, advanced EGFR-positive non-small cell lung cancer, according to updated phase 3 study results from the ARCHER 1050 trial presented at ASCO Annual Meeting. Read More.
FDA approves Keytruda for primary mediastinal large B-cell lymphoma
The FDA expanded the approval of pembrolizumab to include the treatment of adult and pediatric patients with primary mediastinal large B-cell lymphoma who have refractory disease or who relapsed after two or more prior lines of therapy. Read More.